ArticleCureus2021
Clinical Impact of Reporting Coronary Artery Calcium Scores of Non-Gated Chest Computed Tomography on Statin Management.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Prevalence and clinical implications of coronary artery calcium scoring on non-gated thoracic computed tomography: a systematic review and meta-analysis.European radiology · 2024Pooled it
- Reporting Coronary Artery Calcium on Low-Dose Computed Tomography Impacts Statin Management in a Lung Cancer Screening Population.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Article
- Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Coronary artery calcium (CAC) scoring is used as a screening tool for patients with intermediate 10-year arteriosclerotic cardiovascular disease (ASCVD) risk. Results obtained on non-contrast non-gated chest CT (ngCCT) correlate well to those obtained on gated CTs. This paper aims to determine how the routine reporting of CAC scores on ngCCT scans with ASCVD risk of less than 12.5% would change statin management. Methods Data of all patients scanned on a single CT scanner during a four-month window were reviewed. A total of 521 eligible scans were identified. After removing duplicate scans and scans from patients who were not in the age range of 40-75 years, 370 scans remained. Patients were excluded if they had documented ASCVD, type 2 diabetes mellitus, or low-density lipoprotein (LDL) > 190 mg/dL, or if they had ASCVD risk of greater than 12.5%. Ultimately, 36 scans were included in the study. Results Of the 36 patients who qualified, 10 were low-risk (ASCVD risk<5%), 13 were intermediate-risk (ASCVD risk 5-7.5%), and 13 were high-risk (ASCVD risk 7.5%-12.5%). A CAC score of 300 was used as a cutoff for recommending prescribing statins and 0 was used as a cutoff for recommending de-prescribing statins. In 63% of patients (23/36), CAC scoring altered statin recommendations. This included 11/13 (85%) intermediate-risk patients, 6/13 (46%) high-risk patients, and 6/10 (60%) low-risk patients. Conclusions Reporting CAC on ngCCTs obtained for other reasons can significantly impact statin prescribing practices. This may improve cost, patient satisfaction, and patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.